ORIC PHARMACEUTICALS, INC. Operating Lease Cost
ORIC PHARMACEUTICALS, INC. (ORIC) reported Operating Lease Cost of $3.11 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-23
- ORIC PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2021-12-31 was $600.00K.
- ORIC PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2021-09-30 was $500.00K.
- ORIC PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2021-06-30 was $300.00K.
- ORIC PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2021-03-31 was $300.00K.
- ORIC PHARMACEUTICALS, INC. operating lease, cost for fiscal 2025 was $3.11M, a 10.00% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. operating lease, cost for fiscal 2024 was $2.83M, a 4.20% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. operating lease, cost for fiscal 2023 was $2.71M, a 2.26% increase from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. operating lease, cost for fiscal 2022 was $2.65M, a 47.50% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $3.11M 10-K · filed 2026-02-23 | ||||
| 2024-12-31 | $2.83M 10-K · filed 2026-02-23 | ||||
| 2023-12-31 | $2.71M 10-K · filed 2025-02-18 | ||||
| 2022-12-31 | $2.65M 10-K · filed 2024-03-11 | $2.70M 10-K · filed 2023-03-16 | |||
| 2021-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.10M derived: sum of 2 quarters · filed 2023-03-16 | $1.40M derived: sum of 3 quarters · filed 2023-03-16 | $1.80M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $500.00K 10-Q · filed 2021-11-08 | $800.00K derived: sum of 2 quarters · filed 2021-11-08 | $1.20M 10-Q · filed 2021-11-08 | ||
| 2021-06-30 | $300.00K 10-Q · filed 2021-08-10 | $700.00K 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $300.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |